Cargando…
Long-Term Treatment of Postmenopausal Osteoporosis
Osteoporosis is an incurable chronic condition, like heart disease, diabetes, or hypertension. A large gap currently exists in the primary prevention of fractures, and studies show that an estimated 80% to 90% of adults do not receive appropriate osteoporosis management even in the secondary prevent...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Endocrine Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258325/ https://www.ncbi.nlm.nih.gov/pubmed/34154042 http://dx.doi.org/10.3803/EnM.2021.301 |
_version_ | 1783718481050468352 |
---|---|
author | Brown, Jacques P. |
author_facet | Brown, Jacques P. |
author_sort | Brown, Jacques P. |
collection | PubMed |
description | Osteoporosis is an incurable chronic condition, like heart disease, diabetes, or hypertension. A large gap currently exists in the primary prevention of fractures, and studies show that an estimated 80% to 90% of adults do not receive appropriate osteoporosis management even in the secondary prevention setting. Case finding strategies have been developed and effective pharmacological interventions are available. This publication addresses how best to use the pharmacological options available for postmenopausal osteoporosis to provide lifelong fracture protection in patients at high and very high risk of fracture. The benefit of osteoporosis therapies far outweighs the rare risks. |
format | Online Article Text |
id | pubmed-8258325 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Korean Endocrine Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-82583252021-07-19 Long-Term Treatment of Postmenopausal Osteoporosis Brown, Jacques P. Endocrinol Metab (Seoul) Review Article Osteoporosis is an incurable chronic condition, like heart disease, diabetes, or hypertension. A large gap currently exists in the primary prevention of fractures, and studies show that an estimated 80% to 90% of adults do not receive appropriate osteoporosis management even in the secondary prevention setting. Case finding strategies have been developed and effective pharmacological interventions are available. This publication addresses how best to use the pharmacological options available for postmenopausal osteoporosis to provide lifelong fracture protection in patients at high and very high risk of fracture. The benefit of osteoporosis therapies far outweighs the rare risks. Korean Endocrine Society 2021-06 2021-06-22 /pmc/articles/PMC8258325/ /pubmed/34154042 http://dx.doi.org/10.3803/EnM.2021.301 Text en Copyright © 2021 Korean Endocrine Society https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Brown, Jacques P. Long-Term Treatment of Postmenopausal Osteoporosis |
title | Long-Term Treatment of Postmenopausal Osteoporosis |
title_full | Long-Term Treatment of Postmenopausal Osteoporosis |
title_fullStr | Long-Term Treatment of Postmenopausal Osteoporosis |
title_full_unstemmed | Long-Term Treatment of Postmenopausal Osteoporosis |
title_short | Long-Term Treatment of Postmenopausal Osteoporosis |
title_sort | long-term treatment of postmenopausal osteoporosis |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258325/ https://www.ncbi.nlm.nih.gov/pubmed/34154042 http://dx.doi.org/10.3803/EnM.2021.301 |
work_keys_str_mv | AT brownjacquesp longtermtreatmentofpostmenopausalosteoporosis |